Extrahepatic metabolism of ibrutinib

Ibrutinib is a first-in-class Bruton’s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally their excretion in feces and urine occurs. These metabolites...

Descripción completa

Detalles Bibliográficos
Autores principales: Rood, Johannes J. M., Jamalpoor, Amer, van Hoppe, Stephanie, van Haren, Matthijs J., Wasmann, Roeland E., Janssen, Manoe J., Schinkel, Alfred H., Masereeuw, Rosalinde, Beijnen, Jos H., Sparidans, Rolf W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851014/
https://www.ncbi.nlm.nih.gov/pubmed/32623551
http://dx.doi.org/10.1007/s10637-020-00970-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851014/
https://www.ncbi.nlm.nih.gov/pubmed/32623551
http://dx.doi.org/10.1007/s10637-020-00970-x

Ejemplares similares